Suppr超能文献

甲状腺嗜酸细胞癌中的BRAF K601E突变:一例报告及文献综述

BRAF K601E Mutation in Oncocytic Carcinoma of the Thyroid: A Case Report and Literature Review.

作者信息

Matrone Antonio, Citro Fabrizia, Gambale Carla, Prete Alessandro, Minaldi Elisa, Ciampi Raffaele, Ramone Teresa, Materazzi Gabriele, Torregrossa Liborio, Elisei Rossella

机构信息

Unit of Endocrinology, Department of Clinical and Experimental Medicine, Pisa University Hospital, 56124 Pisa, Italy.

Endocrine Surgery Unit, Department of Surgical, Medical, Molecular Pathology and Critical Area, Pisa University Hospital, 56126 Pisa, Italy.

出版信息

J Clin Med. 2023 Nov 7;12(22):6970. doi: 10.3390/jcm12226970.

Abstract

BACKGROUND

Thyroid carcinoma (TC) is the most common endocrine cancer, with papillary thyroid carcinoma (PTC) being the most common subtype. BRAF and RAS oncogene were characterized as the most frequently altered genes in PTC, with a strong association between genotype and histotype. The most common mutation in BRAF gene is V600E and is prevalent in classic and aggressive variants of PTC, while BRAF K601E mutation is the most common among the other rare BRAF mutations. BRAF K601E mutated thyroid carcinomas are usually characterized by low aggressiveness, except for anecdotal cases of poorly differentiated TC.

CASE PRESENTATION

We described a case of oncocytic carcinoma of the thyroid (OCA) with an aggressive clinical course, including widespread metastasis and resistance to radioiodine treatment. Molecular analysis revealed the exclusive presence of the BRAF K601E mutation in both primary tumor and metastatic lesions. Accordingly, a revision of the literature about aggressive TC cases carrying BRAF K601E mutation was performed.

CONCLUSION

Although rare, this case emphasizes the relevance of considering BRAF K601E mutation in advanced non-PTC thyroid carcinomas, since it can be considered an actionable mutation for target therapies.

摘要

背景

甲状腺癌(TC)是最常见的内分泌癌,其中乳头状甲状腺癌(PTC)是最常见的亚型。BRAF和RAS癌基因被认为是PTC中最常发生改变的基因,其基因型与组织类型之间存在密切关联。BRAF基因最常见的突变是V600E,在PTC的经典型和侵袭性变体中普遍存在,而BRAF K601E突变是其他罕见BRAF突变中最常见的。BRAF K601E突变的甲状腺癌通常具有低侵袭性,但也有少数低分化TC的病例报道。

病例报告

我们描述了一例甲状腺嗜酸细胞癌(OCA),其临床病程具有侵袭性,包括广泛转移和对放射性碘治疗耐药。分子分析显示,原发肿瘤和转移灶中均仅存在BRAF K601E突变。因此,我们对携带BRAF K601E突变的侵袭性TC病例的文献进行了回顾。

结论

尽管罕见,但该病例强调了在晚期非PTC甲状腺癌中考虑BRAF K601E突变的重要性,因为它可被视为靶向治疗的一个可操作的突变。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d9/10672186/f208641e8268/jcm-12-06970-g001.jpg

相似文献

2
Histopathologic and Clinical Characterization of Thyroid Tumors Carrying the BRAF(K601E) Mutation.
Thyroid. 2016 Feb;26(2):242-7. doi: 10.1089/thy.2015.0227. Epub 2015 Dec 17.
3
Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
World J Surg. 2008 May;32(5):722-8. doi: 10.1007/s00268-007-9431-6.
5
BRAF Mutation in a Follicular Thyroid Adenoma: A Case Report.
Int J Surg Pathol. 2017 Jun;25(4):348-351. doi: 10.1177/1066896916688083. Epub 2017 Jan 23.
7
BRAF(K601E) mutation in a patient with a follicular thyroid carcinoma.
Thyroid. 2011 Dec;21(12):1393-6. doi: 10.1089/thy.2011.0120.
8
BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer.
Int J Endocrinol. 2015;2015:138734. doi: 10.1155/2015/138734. Epub 2015 Nov 26.

引用本文的文献

1
Biomarkers in Thyroid Cancer: Emerging Opportunities from Non-Coding RNAs and Mitochondrial Space.
Int J Mol Sci. 2024 Jun 18;25(12):6719. doi: 10.3390/ijms25126719.

本文引用的文献

1
Insight of novel biomarkers for papillary thyroid carcinoma through multiomics.
Front Oncol. 2023 Sep 19;13:1269751. doi: 10.3389/fonc.2023.1269751. eCollection 2023.
3
Immunohistochemistry in the pathologic diagnosis and management of thyroid neoplasms.
Front Endocrinol (Lausanne). 2023 May 31;14:1198099. doi: 10.3389/fendo.2023.1198099. eCollection 2023.
4
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading.
Endocr Relat Cancer. 2022 Dec 22;30(2). doi: 10.1530/ERC-22-0293. Print 2023 Feb 1.
6
Thyroid Carcinoma Showing Thymus-like Differentiation (CASTLE): A Case Report.
Life (Basel). 2022 Aug 26;12(9):1314. doi: 10.3390/life12091314.
7
Core Needle Biopsy Can Early and Precisely Identify Large Thyroid Masses.
Front Oncol. 2022 Apr 5;12:854755. doi: 10.3389/fonc.2022.854755. eCollection 2022.
8
Overview of the 2022 WHO Classification of Thyroid Neoplasms.
Endocr Pathol. 2022 Mar;33(1):27-63. doi: 10.1007/s12022-022-09707-3. Epub 2022 Mar 14.
9
Genetics, Diagnosis, and Management of Hürthle Cell Thyroid Neoplasms.
Front Endocrinol (Lausanne). 2021 Jun 10;12:696386. doi: 10.3389/fendo.2021.696386. eCollection 2021.
10
Differentiated Thyroid Cancer, From Active Surveillance to Advanced Therapy: Toward a Personalized Medicine.
Front Endocrinol (Lausanne). 2020 Jan 8;10:884. doi: 10.3389/fendo.2019.00884. eCollection 2019.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验